COG AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk BLymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
To define optimal intrathecal agents for use with effective chemotherapy with minimal increase in toxicity nad/or burden of therapy for children with HR-ALL. Patient will be randomized to post-induction therapy with a modified BFM backbone that includes a single Interim Maintenance (IM) phase with high dose methotrexate and a single Delayed Intensification (DI) phase with either intrathecal methotrexate only.
Study Number: 

NCG 206911

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail